Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.52 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.48 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.48 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.48 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.48 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.48 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 6/20 | 0.46 |
| ▸ | REN | P00797 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 2/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6308523 | 1.00 | KLK5 (0.52) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7277293 | 0.87 | KLK5 (0.51) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7364763 | 0.87 | KLK5 (0.51) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9725769 | 0.87 | KLK5 (0.51) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6356044 | 0.87 | KLK5 (0.51) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6663844 | 0.84 | KLK5 (0.41) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7492257 | 0.84 | PSEN1 (0.57) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6305527 | 0.83 | KLK5 (0.50) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6311500 | 0.83 | KLK5 (0.50) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6312323 | 0.83 | KLK5 (0.50) | KLK5PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050159460-A1 | Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease | ELAN PHARMACEUTICALS | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159460-A1 | Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease | BACE1, APP, BACE2 | KLK5 1643/4885PSEN1 5/4885PSEN2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.